{"id":"NCT01517802","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","officialTitle":"A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03-28","primaryCompletion":"2021-04-22","completion":"2021-04-22","firstPosted":"2012-01-25","resultsPosted":"2022-05-10","lastUpdate":"2022-05-10"},"enrollment":32,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Castration-resistant Prostate Cancer","Metastatic Breast Cancer"],"interventions":[{"type":"DRUG","name":"Abiraterone acetate","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]}],"arms":[{"label":"Abiraterone acetate","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.","primaryOutcome":{"measure":"Number of Participants With Serious Adverse Events (SAEs)","timeFrame":"Up to 9 years","effectByArm":[{"arm":"Abiraterone Acetate + Prednisone/Prednisolone","deltaMin":16,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":22,"countries":["United States","Australia","Belgium","Germany","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":31},"commonTop":["Lower Respiratory Tract Infection","Urinary Tract Infection","Dehydration","Cerebrovascular Accident","Encephalopathy"]}}